Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs

Archives of Ophthalmology
Angelo P TannaRobert M Feldman

Abstract

To perform a meta-analysis to estimate the intraocular pressure (IOP)-lowering efficacy and safety of alpha(2)-adrenergic agonists (AAs), beta-adrenergic antagonists (BBs), and topical carbonic anhydrase inhibitors (TCAIs) when used in combination with a prostaglandin analog (PGA). MEDLINE, Embase, and the Cochrane Controlled Trials Register were systematically searched for relevant articles in April 2009. Ten observer-masked randomized clinical trials that reported baseline IOP while receiving PGA monotherapy and follow-up IOP while receiving combination therapy were identified. The pooled IOP-lowering efficacy achieved with each class of adjunctive agent was calculated using random-effects models. The frequencies of adverse events were pooled across studies and compared using Fisher exact test. Mean diurnal IOP reduction achieved in all 3 groups was statistically similar (P = .22). At trough, IOP reduction was greater in the TCAI (P < .001) and BB (P < .001) groups than in the AA group. Peak IOP reduction was similar in the 3 groups (P = .66). Eye or eyelid pain or burning and xerostomia were significantly more common in the AA group. Fatigue, weakness, or dizziness was more common in the AA and BB groups compared with the TC...Continue Reading

Citations

Feb 9, 2012·Journal of Ophthalmology·Ammar M Al-MahmoodDeepak P Edward
Jul 28, 2011·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Gábor HollóWilliam C Stewart
Oct 11, 2012·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Hiroshi OhguroSaeko Yagi
Apr 5, 2013·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Anastasios G P KonstasJohn R Samples
Feb 3, 2015·Expert Opinion on Drug Safety·Gábor Holló, Andreas Katsanos
Sep 5, 2015·Acta Ophthalmologica·Hidenobu TaniharaUNKNOWN K-115 Clinical Study Group
Jul 8, 2016·Advances in Therapy·Tadashi NakanoMasayuki Tatemichi
Jan 2, 2014·Therapeutic Advances in Chronic Disease·Deepak Sambhara, Ahmad A Aref
Jan 17, 2015·Current Opinion in Ophthalmology·Angelo P Tanna, Albert B Lin
Feb 16, 2018·Japanese Journal of Ophthalmology·Megumi Honjo, Hidenobu Tanihara
Feb 18, 2016·Asia-Pacific Journal of Ophthalmology·Anjum CheemaKuldev Singh
Feb 18, 2016·Asia-Pacific Journal of Ophthalmology·Robert T Chang, Kuldev Singh
Apr 11, 2021·Ophthalmology. Glaucoma·Alisa J PragerAngelo P Tanna
May 1, 2021·The Medical Clinics of North America·Jessica Minjy Kang, Angelo P Tanna
Aug 6, 2021·Therapeutic Advances in Ophthalmology·Lisa-Marie AndersMatthias C Grieshaber
Aug 29, 2021·International Ophthalmology·Bhawesh Chandra SahaBibhuti Prasanna Sinha

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Related Papers

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
Haruhisa FukayamaMasahiro Umino
International Journal of Paediatric Dentistry
Mats Bågesund, Parisa Tabrizi
© 2021 Meta ULC. All rights reserved